

BLOOD PRODUCTS ADVISORY COMMITTEE

May 9, 2024

Revised Discussion Questions

1. Please comment on FDA's proposed strategies for selectively testing blood donations from donors at risk for malaria using an FDA-licensed NAT.

Strategy 1A: Selective testing for history of malaria, history of prior residence in malaria-endemic country, history of travel to a malaria-endemic area

Strategy 1B: One-time testing of all donors and selective testing for history of malaria and history of travel to a malaria-endemic area

2. Please comment on FDA's proposal that blood establishments should implement time-limited NAT screening of all donations collected in area(s) of the U.S. when a single case of local mosquito-borne malaria is reported by public health authorities.